H. Siltberg et al., Validation of cough-induced leak point pressure measurement in the evaluation of pharmacological treatment of stress incontinence, NEUROUROL U, 18(6), 1999, pp. 591-602
To improve routines in clinical practice and research, it is important that
new tests are thoroughly evaluated before they,gain widespread application
. This includes establishing the reliability and validity of the new test.
The purpose of this study was to establish the construct and criterion vali
dity of cough-induced leak point pressure (CILPP) measurement. Data on CILP
P, maximum urethral pressure (MUP), and a short-term pad test from a phase-
I trial of a new pharmacological agent (LS 4416), developed for the treatme
nt of stress incontinence, was used to test the validity of CILPP. Fifteen
post-menopausal women with stress incontinence were studied. Phenylpropanol
amine (PPA) was used as a positive control. Administration of PPA produced
a statistically significant increase in MUP and CILPP. There was a signific
antly better effect of treatment, expressed as an increase in MUP at 1.5 hr
, when PPA was used than with placebo or LS 4416. When CILPP was used to de
tect change after therapy, PPA produced a significantly greater increase in
CILPP than did placebo (least square mean of difference 17.25, P = 0.0202)
. There was a moderate but statistically significant correlation between CI
LPP and the short-term Pad Test. Construct validity was demonstrated by the
ability of CILPP to detect Limited improvement in patients with stress inc
ontinence. Criterion validity was established by the correlation of CILPP t
o a short-term Pad Test. We propose that, thanks to its greater methodologi
cal qualities, leak point pressure measurement should be adopted as a stand
ard method to ascertain the effect of treatment in patients with stress inc
ontinence. (C) 1999 Wiley-Liss,Inc.